Since Iovance Biotherapeutics Inc. (NASDAQ:IOVA) and Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation of both companies.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics Inc.	N/A	0.00	123.58M	-1.37	0.00
Clementia Pharmaceuticals Inc.	N/A	0.00	50.56M	-2.03	0.00

In table 1 we can see Iovance Biotherapeutics Inc. and Clementia Pharmaceuticals Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 provides us the return on equity, return on assets and net margins of both companies.

	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics Inc.	0.00%	-43.7%	-41.3%
Clementia Pharmaceuticals Inc.	0.00%	-40.7%	-38.2%

Liquidity

The Current Ratio of Iovance Biotherapeutics Inc. is 15.9 while its Quick Ratio stands at 15.9. The Current Ratio of rival Clementia Pharmaceuticals Inc. is 10 and its Quick Ratio is has 10. Iovance Biotherapeutics Inc. is better equipped to clear short and long-term obligations than Clementia Pharmaceuticals Inc.

Institutional & Insider Ownership

Institutional investors held 0% of Iovance Biotherapeutics Inc. shares and 84.1% of Clementia Pharmaceuticals Inc. shares. Insiders held 0.4% of Iovance Biotherapeutics Inc. shares. Competitively, Clementia Pharmaceuticals Inc. has 5.69% of it’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Iovance Biotherapeutics Inc.	7.34%	23.06%	21.6%	-31.55%	-37.96%	27.23%
Clementia Pharmaceuticals Inc.	-1.19%	89.48%	80.32%	165.46%	51.83%	118.96%

For the past year Iovance Biotherapeutics Inc.’s stock price has smaller growth than Clementia Pharmaceuticals Inc.

Summary

On 4 of the 6 factors Clementia Pharmaceuticals Inc. beats Iovance Biotherapeutics Inc.

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company’s lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients’ tumors for the treatment of patients with refractory metastatic melanoma. It is also developing LN-145 to treat cervical and head and neck cancers. The company has a patent license agreement with the National Institutes of Health for technologies relating to autologous TIL adoptive cell therapy products for the treatment of metastatic melanoma, lung, breast, bladder, and HPV-positive cancers; cooperative research and development agreement with the National Cancer Institute to develop adoptive cell immunotherapies that are designed to destroy metastatic melanoma cells using a patient’s TIL, as well as for the treatment of cervical, head and neck, lung, bladder, and breast cancer; and manufacturing services agreement with Lonza Walkersville, Inc. and WuXi Apptech, Inc. to manufacture, package, ship, and handle quality assurance and quality control of clinical trials for TIL products. In addition, it has collaboration and license agreements with Medimmune, Inc. to conduct clinical and preclinical research in immuno-oncology; H. Lee Moffitt Cancer Center and Research Institute to research and develop adoptive TIL cell therapy; PolyBioCept, AB to develop, manufacture, market, and genetically engineer TIL; and the University of Texas MD Anderson Cancer Center for multi-arm clinical trials for TIL therapy. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was founded in 2007 and is headquartered in San Carlos, California.

Clementia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops disease-modifying treatments for patients suffering from debilitating bone and other diseases. Its lead product candidate is palovarotene, an oral small molecule that binds and activates retinoic acid receptor gamma, and prevents abnormal new bone formation, as well as scar tissue formation in various tissues in animal models. The company is developing palovarotene for the treatment of fibrodysplasia ossificans progressiva and multiple osteochondroma, as well as has one Phase III and Phase II/III trials for two separate indications. Clementia Pharmaceuticals Inc. was founded in 2010 and is based in Montreal, Canada.